In January 2018, the Delhi High Court ruled that the ₹3,500 crore arbitration award that Daiichi Sankyo won against the Singh brothers for concealing information about the erstwhile Ranbaxy Laboratories, was enforceable in India.
Daiichi Sankyo then filed a petition to enforce the arbitral award passed by a Singapore tribunal in 2016.
The Securities and Exchange Board of India (SEBI) had also barred the Singh brothers from accessing the securities market for a period of three years. They have also been restrained from being associated as directors or key managerial personnel in a listed company or SEBI-registered intermediary of any market infrastructure institution (MII).
Source: Barandbench
